UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 8, 2016
ELEVEN BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware | 001-36296 | 26-2025616 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
215 First Street, Suite 400 Cambridge, MA | 02142 | |
(Address of Principal Executive Offices) | (Zip Code) | |
Registrant’s telephone number, including area code: (617) 871-9911
None
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07 | Submission of Matters to a Vote of Security Holders |
Eleven Biotherapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 8, 2016. The following is a summary of the matters voted on at that meeting.
a) | The stockholders of the Company elected Paul Chaney, Wendy Dixon, Ph.D. and Jay Duker, M.D. as class II directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2019. The results of the stockholders’ vote with respect to the election of the class II directors were as follows: | |
Name | Votes For | Votes Withheld | Broker Non- Votes | ||||||
Paul Chaney | 9,031,063 | 213,199 | 6,085,138 | ||||||
Wendy Dixon, Ph.D. | 8,996,713 | 247,549 | 6,085,138 | ||||||
Jay Duker, M.D. | 8,997,323 | 246,939 | 6,085,138 | ||||||
b) | The stockholders of the Company ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016. The results of the stockholders’ vote with respect to such ratification were as follows: | |
For | Against | Abstain | Broker Non-Votes | |||
14,804,136 | 245,333 | 279,931 | 0 | |||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ELEVEN BIOTHERAPEUTICS, INC. | ||||
Date: June 10, 2016 | By: | /s/ Abbie C. Celniker | ||
Abbie C. Celniker, Ph.D. President & Chief Executive Officer | ||||